Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective open-label single-arm study of entecavir in treatment-naive chronic hepatitis B at a tertiary care center in Thailand
TCTR20250823001Phase 4Not yet recruiting
- Sponsor
- Berlin Pharmaceutical
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of entecavir in Chronic Hepatitis B (CHB), sponsored by Berlin Pharmaceutical. Primary endpoints: Efficacy of entecavir in treatment-naive chronic hepatitis B and Safety of entecavir in treatment-naive chronic hepatitis B. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on TCTR20250823001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250823001.